Table 1.
Characteristics | Total | CAR | PLR | NLR | ||||||
---|---|---|---|---|---|---|---|---|---|---|
n=235 | LCAR | HCAR | P | LPLR | HPLR | P | LNLR | HNLR | P | |
Age (years) | ||||||||||
≤18 | 125 | 77 | 45 | 0.074 | 65 | 60 | 0.867 | 61 | 64 | 0.019 |
>18 | 110 | 55 | 55 | 56 | 54 | 37 | 73 | |||
Sex | ||||||||||
Male | 156 | 83 | 73 | 0.198 | 79 | 77 | 0.715 | 61 | 95 | 0.256 |
Female | 79 | 49 | 30 | 42 | 37 | 37 | 42 | |||
Location | ||||||||||
Extremities | 208 | 116 | 92 | 0.731 | 108 | 100 | 0.712 | 90 | 118 | 0.176 |
Non-extremities | 27 | 16 | 11 | 13 | 14 | 8 | 19 | |||
Tumor size | ||||||||||
≤8cm | 115 | 79 | 36 | <0.001 | 71 | 44 | 0.002 | 54 | 61 | 0.110 |
>8cm | 120 | 53 | 67 | 50 | 70 | 44 | 76 | |||
Enneking | ||||||||||
I | 31 | 26 | 5 | 0.002 | 19 | 12 | 0.222 | 18 | 13 | 0.015 |
II | 119 | 66 | 53 | 64 | 55 | 54 | 65 | |||
III | 85 | 40 | 45 | 38 | 47 | 26 | 59 | |||
Subtype | ||||||||||
Conventional osteosarcoma | 152 | 85 | 67 | 0.772 | 78 | 74 | 0.945 | 59 | 93 | 0.596 |
Telangiectatic osteosarcoma | 15 | 10 | 5 | 6 | 9 | 5 | 10 | |||
Small cell osteosarcoma | 4 | 1 | 3 | 3 | 1 | 3 | 1 | |||
Parosteal osteosarcoma | 27 | 15 | 12 | 14 | 13 | 12 | 15 | |||
Periosteal osteosarcoma | 5 | 4 | 1 | 3 | 2 | 3 | 2 | |||
High grade surface osteosarcoma | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |||
Low-grade central osteosarcoma | 30 | 16 | 14 | 16 | 14 | 15 | 15 | |||
Pathological fracture | ||||||||||
No | 211 | 120 | 91 | 0.520 | 111 | 100 | 0.310 | 86 | 125 | 0.384 |
Yes | 24 | 12 | 12 | 10 | 14 | 12 | 12 | |||
NACT | ||||||||||
No | 95 | 51 | 44 | 0.527 | 47 | 48 | 0.611 | 34 | 61 | 0.130 |
Yes | 140 | 81 | 59 | 74 | 66 | 64 | 76 | |||
Surgery | ||||||||||
No | 31 | 13 | 18 | 0.086 | 10 | 21 | 0.021 | 11 | 20 | 0.451 |
Yes | 204 | 119 | 85 | 111 | 93 | 87 | 117 | |||
alkaline phosphatase | ||||||||||
Normal | 99 | 62 | 37 | 0.089 | 49 | 50 | 0.602 | 47 | 52 | 0.126 |
Elevated | 136 | 70 | 66 | 72 | 64 | 51 | 85 |
CAR C-reactive protein-to-albumin ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, NACT neoadjuvant chemotherapy